Licensing, mRNA for Cancer Treatment, and Scalability for Viral Vectors
Cell & Gene
The most valuable resource for professionals who make their living in the cell & gene therapies industry.
TRENDING CONTENT - Catch Up
What are some of the key issues that licensors and licensees should consider when negotiating and drafting cell or gene therapy license agreements? Answers from Brigid Bondoc , Matt Ferry , Robert Grohmann, LL.M. , and Dr. Wolfgang Schönig at Morrison Foerster
As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.
Dr. Peter Marks and Dr. Nicole Verdun discuss 2024 industry changes, emphasizing pivotal roles, manufacturing challenges, and pediatric treatment pathways, highlighting the importance of ongoing dialogue for transformative therapies.
Explore the wide range of solutions to facilitate the delivery of gene therapy by addressing the challenges related to viral vector manufacture and scale-up. By Henry George , and Lisa Freeman-Cook , MilliporeSigma
Compliance with potency tests, FDA regulatory frameworks, and standard operating procedures is important to the efficacy, purity, and safety of CGT products and treatments. Read about the current state of the industry, the challenges associated with potency assays, and measuring product potency throughout the manufacturing process. Source: Bio-Rad Laboratories
Recommended by LinkedIn
Experts explore challenges surrounding raw materials – both quality and supply – as well as the importance of achieving more efficient scale-out and turnaround times for mRNA production. Featuring J. Andrew Case and Daniel G. Getts.
CELL & GENE: THE PODCAST - Listen Here
“We're evaluating the potential for cellular rejuvenation to treat a broad number of different diseases of aging, and we already have compelling preclinical data in neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia, as well as other ophthalmic disorders, including age-related macular degeneration and other forms of retinal degeneration." -- Sharon Rosenzweig-Lipson , CSO, Life Biosciences
CELL & GENE LIVE! - Register Now
Stem cells are the backbone of many allogeneic, “off-the-shelf” therapies. Where they come from affects product development and supply chain logistics. What temperatures are ideal? How do you work with existing infrastructure?
Coeptis Therapeutics and Deverra Therapeutics ’ Dr. Colleen Delaney and Gamida Cell Ltd. ’s Nick Bayrakdarian join Cell & Gene Live’s Tyler Menichiello to discuss product development and supply chain logistic challenges affected by stem cell collection origins. Supported by Charter Medical and Bio-Techne .